Brainsightai

BrainSightAI is a Bengaluru-based deep-tech neuroscience company that builds AI- and machine-learning-based neuroimaging software for clinicians treating brain disorders. Its main product, VoxelBox, is a neuroinformatics/connectomics platform that processes functional MRI data — in particular resting-state fMRI — together with MRI oxygenation and diffusion techniques to map both structural and functional connectivity and generate personalised three-dimensional brain maps. A radiologist uploads an MRI scan and the platform returns a detailed brain map within about an hour, giving neurosurgeons, neurologists and psychiatrists a connectomic view of networks governing language, sensory-motor and cognitive function. In surgical use, the output can be displayed on neuro-navigation systems so that operators can choose alternative routes when a tumour lies near a functional area; the platform is also used for diagnosis, surgical planning and treatment monitoring [0][5][6][7].

The company's second product, Snowdrop, is a patient-care application that combines data from patients, caregivers and clinicians to support treatment-schedule compliance and to build holistic patient profiles [5][6]. R&D funding from the January 2025 round is also being directed at a caregiver-focused app for families of patients with brain disorders [4][5].

The initial focus was a neuro-informatics platform serving psychiatrists, but early connectomics work attracted neurosurgeons, and brain tumour and neuro-oncology cases became the primary commercial entry point, with results also reported in epilepsy. The stated roadmap extends to multiple sclerosis, Parkinson's disease, major depression and OCD, with a longer-term ambition of a personalised 3D "brain twin" per patient. Clinical trials with hospital partners cover Alzheimer's and other dementias, brain tumours and neuro-oncology, depression, anxiety, BPD, NPD and other psychiatric disorders, Parkinson's and movement disorders, and stroke and cerebrovascular disease [2][6][7].

Founding story

Laina Emmanuel and Dr Rimjhim Agrawal met in a 2019 Entrepreneur First cohort in Bengaluru, the accelerator that pairs prospective co-founders, and founded BrainSightAI that year. Emmanuel is an electronics and communications engineer with a degree from NIT Calicut and an MBA in marketing and healthcare from the Indian School of Business, with roughly 15 years of experience (as of 2019) in healthcare management, technology and policy, including consulting for the Government of India and the Clinton Health Access Initiative and product work at NetApp and Infosys' Cisco offshore development centre. Agrawal holds a PhD from NIMHANS in machine learning applied to psychiatry, studied earlier at the Vellore Institute of Technology, and has published papers and patents on computational psychiatry and machine learning for neuroimaging; her doctoral work on brain-imaging markers for schizophrenia and OCD formed the scientific basis for VoxelBox. Agrawal wanted to translate her research into real-world applications, and Emmanuel's healthcare business background complemented that research depth [1][4][6][7].

Business model

BrainSightAI sells software-as-a-medical-device to hospitals, primarily through neurosurgery and radiology departments, having converted pilot deployments at around 40 hospitals into commercial contracts after receiving CDSCO certification. It also runs clinical studies and trials with hospital partners and has been supported by research grants and accelerator programmes [0][4][6].

Commercial contracts with hospitals for the VoxelBox platform following CDSCO software-as-a-medical-device licensing; the CEO has described an ambition to reach a $100 million annual recurring revenue run rate by scaling in India and expanding globally, implying a recurring/subscription orientation [5][6].

Traction

Collaborates with over 40 hospitals across India, primarily in neurosurgery and radiology, with a focus on brain tumour cases; CDSCO certification in March 2024 enabled conversion of many pilots into commercial contracts, and the company stated a target of reaching 100 hospitals. Ongoing clinical trials are listed with St John's (ongoing), Manipal, SRMC and Max (just started). The platform is reported as used by neurosurgeons in brain tumour cases with results in epilepsy treatment [0][2][4][5][6][7].

Latest developments

In January 2025 the company raised $5 million in a pre-Series A round led by IAN Alpha Fund with IvyCap Ventures, Silver Needle and existing investors, earmarked for Indian expansion, FDA certification, international exploration and R&D on a caregiver app. In June 2025 Forbes India reported the company's focus for the year on raising revenues and reaching 100 hospitals while pursuing US FDA certification. A June 2026 brand-publisher feature lists the company among R&D-backed Indian ventures associated with the Ministry of Education's Bharat Innovates 2026 initiative [4][5][6][7].